Adjust Font Size:

Press Releases

Advanced Cell Technology's VP of Research & Scientific Development, Dr. Robert Lanza, to Deliver Opening Keynote Address at Termis NA 2007 Conference on Regenerative Medicine

Alameda, CA - June 13, 2007 Advanced Cell Technology's (OTCBB:ACTC) Vice President of Research and Scientific Development, Robert Lanza, M.D., will be delivering the opening keynote address at TERMIS NA 2007, a conference focusing on challenges in the fields of regenerative medicine. In Dr. Lanza's address, scheduled for Thursday, June 14, at 8:30 am, he will speak on the use of embryonic stem cells and the role they play in regenerative medicine.

TERMIS, or Tissue Engineering & Regenerative Medicine International Society, is a globally recognized group of scientific professionals practicing in the fields related to regenerative medicine. The conference will include more than 100 scientific presentations comprising the most comprehensive regenerative medicine event in North America.

For more information on the event, please visit "http://regenerate-online.com/":http://regenerate-online.com/index.php.

About Advanced Cell Technology, Inc.

Advanced Cell Technology, Inc. is a biotechnology company applying embryonic stem cell technology in the emerging field of regenerative medicine. The company operates facilities in Alameda, California and Worcester, Massachusetts.

For more information, please visit: "www.advancedcell.com":http://www.advancedcell.com


About TERMIS NA

The Tissue Engineering & Regenerative Medicine International Society (TERMIS) brings together the international community of persons engaged or interested in the field of tissue engineering and regenerative medicine and promotes education and research within the field of tissue engineering and regenerative medicine through regular meetings, publications and other forms of communication. The Society also serves as an international forum to promote the informed discussion of challenges and therapeutic benefits of the application of tissue engineering and regenerative medicine technologies.

Most importantly, the Society is committed to bringing you closer to key professionals to support your mutual understanding of the field, accelerate your research in the field and to enable you to contribute to the ultimate care of patients in this very important way. To affect this interchange of information, the Society has endorsed the journal, Tissue Engineering, as its official publication and has negotiated a reduced subscription rate for members. In addition, the TERMIS publishes a quarterly newsletter for its members to keep them abreast of developments in the field. The TERMIS World Congress Meeting will be held every three years. In the interim years the Continental Chapters will host annual meetings to promote tissue engineering and regenerative medicine research regionally.

Forward-Looking Statements

Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words "will," "believes," "plans," "anticipates," "expects," "estimates," and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company's periodic reports, including the report on Form 10-QSB for the quarter ended March 31, 2007. Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.

Forward-looking statements are based on the beliefs, opinions, and expectations of the company's management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change.

Contact

The Investor Relations Group
Investors: James Carbonara or Joseph Kessler, 212-825-3210
Media: Bill Douglass, 212-825-3210

Press Contact





Download PDF


ACT-_Lanza.pdf

To view PDF Files, you must have Acrobat Reader.

Download Adobe Acrobat